Last Price$61.4(0.0%)
Market Cap$7,773.1M
22.4%
Industry median - 3.6%
5Y Historical average - 41.8%
63.4%
Industry median - 8.2%
5Y Historical average - 74.6%
63.6%
Industry median - (12.5%)
5Y Historical average - 135.1%
25.5%
Industry median - 10.8%
5Y Historical average - 64.7%
HALO Growth Rating
HALO Growth rating
7.6
HALO Growth rating performance
HALO Growth Metrics
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Competing with HALO Growth
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Growth score | Revenue Growth
(5Y CAGR) | Revenue Growth
(YoY) | Revenue Growth
(FWD) | EPS Growth
(5Y CAGR) | EPS Growth
(YoY) | EPS Growth
(FWD) | FCF Growth
(5Y CAGR) | FCF Growth
(YoY) |
$7,773.1M | 7.6 | 39.0% | 22.4% | 17.2% | N/A | 63.6% | 44.6% | N/A | 25.5% | |
$124.8B | 6.9 | 21.5% | 11.5% | 8.6% | N/A | N/A | (962.4%) | N/A | N/A | |
$77.0B | 5.6 | 12.6% | 8.3% | 2.4% | 16.1% | 10.3% | 3.1% | 12.5% | (5.7%) | |
$34.4B | 6.3 | 106.9% | 127.3% | 76.3% | (9.7%) | (57.5%) | (132.2%) | N/A | (70.8%) | |
$30.7B | 5.4 | 59.2% | 23.0% | 28.6% | (23.2%) | (38.5%) | (26.5%) | (36.7%) | N/A | |
$24.0B | 6.2 | 90.9% | (28.0%) | (28.0%) | 36.5% | N/A | (182.9%) | (3.1%) | N/A | |
$14.5B | 4.0 | 4.5% | (3.8%) | 35.4% | (19.0%) | (9.0%) | 144.6% | 10.7% | (7.3%) | |
$13.8B | 7.5 | 14.7% | 23.6% | 9.1% | N/A | 25.6% | 6.8% | N/A | 44.5% | |
$13.4B | 7.1 | 10.8% | 17.8% | 10.0% | N/A | 152.8% | 48.9% | N/A | 820.5% | |
$13.3B | 6.1 | (100.0%) | N/A | N/A | (0.9%) | (92.8%) | 11.4% | 44.6% | 84.8% | |
$1,846.9M | 5.9 | 50.5% | 50.5% | 50.7% | 25.3% | 20.9% | (35.6%) | 3.3% | (43.8%) |
FAQ
What is the Halozyme Therapeutics, Inc. (HALO) revenue growth?
The Halozyme Therapeutics, Inc. (HALO) revenue growth is 22.4%, which is lower than the industry median of 3.6% and the 5-year historical average of 41.8%.
What is the Halozyme Therapeutics, Inc. (HALO) operating income growth?
The Halozyme Therapeutics, Inc. (HALO) operating income growth is 63.4%, compared to the industry median of 8.2% and the 5-year historical average of 74.6%.
What is the Halozyme Therapeutics, Inc. (HALO) EPS (Earnings Per Share) growth?
The Halozyme Therapeutics, Inc. (HALO) EPS growth is 63.6%, compared to the industry median of (12.5%) and the 5-year historical average of 135.1%.
What is the Halozyme Therapeutics, Inc. (HALO) Free Cash Flow (FCF) growth?
The Halozyme Therapeutics, Inc. (HALO) Free Cash Flow growth is 25.5%, compared to the industry median of 10.8% and the 5-year historical average of 64.7%.